| Description | EC330, a novel steroidal LIF inhibitor showed cytotoxicity in various cancer cell lines and NCI-60 cell line panel at low nano-molar range. |
| In vitro | EC330在软琼脂中阻止了菌落的形成，并抑制了人类脐静脉内皮细胞中的血管生成（管形成）。通过体内外对接研究，EC330与LIF/LIFR复合体结合，并通过阻断LIF-JAK-STAT信号传导，以剂量依赖性方式降低STAT3磷酸化。EC330在过表达LIF的MCF-7细胞中显示出明显的特异性，相较于未过表达的MCF-7细胞。该化合物进一步显示了细胞骨架的破坏，并靶向癌症相关成纤维细胞（CAFs）。 |
| In vivo | EC330处理(0.5和2.5mg/kg) 在卵巢癌(IGROV-1)和三阴性乳腺癌(MDA-MB-231)细胞移植的小鼠模型中，剂量依赖性地减少了肿瘤负担。 |
| molecular weight | 462.57 |
| Molecular formula | C30H32F2O2 |
| CAS | 2016795-77-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 20 mg/mL (43.24 mM) |
| References | 1. Nair H B , Santhamma B , Viswanadhapa S , et al. Abstract LB-208: First-in-class steroidal leukemia inhibitory factor (LIF) inhibitor in targeted cancer therapy[J]. Cancer Research, 2016, 76(14 Supplement):LB-208-LB-208. |